| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In liver hepatocytes, EDP-305 (10 μM, 72 h) directly activates FXR, but not in stellate cells [1]. In HepaRG hepatocytes, EDP-305 (0–5 μM, 16 hours) can down-regulate the expression of CYP7A1 and up-regulate the expression of the FXR target gene SHP [2].
|
|---|---|
| ln Vivo |
EDP-305 (0-30 mg/kg, oral gavage, once daily for 2 weeks) decreases blood indicators of liver injury and reduces hepatic fibrosis in a dose-dependent manner in BDL rats [1]. EDP-305 (0-30 mg/kg, oral gavage, once daily for 6 weeks) decreases liver fibrosis in CDAHFD mice in a dose-dependent manner [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: Hepatic stellate cell (HSC) line, primary HSC and hepatocytes Tested Concentrations: 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Induced SHP and FGF19 mRNA expression in human hepatocytes, but not Expression of downstream targets in star lines is SHP or FGF15/19. RT-PCR[2] Cell Types: HepaRG Hepatocyte Tested Concentrations: 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, 500, 1000, 5000 nM Incubation Duration: 16 hrs (hours) Experimental Results: Dose-dependent increase in FXR target genes CYP7A1 expression was downregulated in , SHP and HepaRG hepatocytes. |
| Animal Protocol |
Animal/Disease Models: Male CD rats (receiving BDL, n=24, n=8 per group) [1]
Doses: 0, 10 and 30 mg/kg Route of Administration: Daily po (oral gavage), starting from the 4th day after BDL Started on day 17 and continued until day 17-18. Experimental Results: Alanine aminotransferase and aspartate aminotransferase were Dramatically diminished. demonstrated a dose-dependent decrease in CPA. Hydroxyproline levels were diminished in whole liver tissue samples. The messenger RNA (mRNA) relative quantification (RQ) of Col1a1 and actin, α2, smooth muscle, and aorta (Acta2) was diminished. Animal/Disease Models: Male C57BL/6 mice (n = 24, fed CDAHFD consisting of 60% kcal fat and 0.1% methionine) [1] Doses: 0, 10 and 30 mg/kg Route of Administration: Daily po (oral gavage) , starting the diet from week 6 and continuing until week 12. Experimental Results: Serum triglycerides were diminished, hydroxyproline and MR liver signal intensity were Dramatically diminished in a dose-dependent manner. The mRNA expression of lysyl oxidase genes Lox and Loxl1-4 diminished in a dose-depe |
| References |
|
| Molecular Formula |
C36H58N2O5S
|
|---|---|
| Molecular Weight |
630.92
|
| CAS # |
1933507-63-1
|
| PubChem CID |
121428882
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
44
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
S(C1C=CC(C(C)(C)C)=CC=1)(NC(NCC[C@@H](C)[C@@]1([H])CC[C@]2([H])[C@]1(C)CC[C@]1([H])[C@@]3(C)CC[C@@H](C[C@]3([H])[C@@H](CC)[C@H]([C@@]12[H])O)O)=O)(=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~158.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.96 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.96 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5850 mL | 7.9249 mL | 15.8499 mL | |
| 5 mM | 0.3170 mL | 1.5850 mL | 3.1700 mL | |
| 10 mM | 0.1585 mL | 0.7925 mL | 1.5850 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
